Autolus Therapeutics plc (Nasdaq: AUTL) reported preliminary second quarter 2026 net product revenue of approximately $45 million for its therapy AUCATZYL, representing a roughly 70% increase over Q1 2026 and more than 100% compared to Q2 2025, according to a press release from the company.

The company also reported a year-to-date gross margin of approximately 35%, up from a negative gross margin of approximately 20% in the second half of 2025. As a result, Autolus raised its full-year 2026 net product revenue guidance to $140–$150 million, from a prior range of $120–$135 million.

Autolus also announced it has entered into a senior credit facility with Perceptive Advisors for notes of up to $250 million in aggregate principal amount. The five-year, interest-only facility includes an initial $75 million tranche issued on July 30, 2026, with an additional $25 million available at Autolus' option for up to six months post-closing. A further $150 million may become available in separate tranches upon achievement of certain pre-specified revenue milestones.

The credit facility bears interest at one-month SOFR, subject to a floor of 3.50%, plus 7.25%. At closing, Autolus issued Perceptive a warrant to purchase up to 3.5 million American Depositary Receipts at an exercise price of $1.9314 per ADS, equal to 125% of the 30-day volume-weighted average price preceding the closing date.

The company said the combined first and second tranches, totaling $100 million, together with existing cash, cash equivalents, and marketable securities, are expected to provide funding into Q2 2028.

Autolus is scheduled to report full second quarter 2026 financial results on August 11, 2026.